Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fostamatinib disodium by Rigel Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According...
Fostamatinib disodium by Rigel Pharmaceuticals for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia....
Fostamatinib disodium by Rigel Pharmaceuticals for Hidradenitis Suppurativa: Likelihood of Approval
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData,...